SENORES Q1 FY27 results at a glance
SENORES PHARMACEUTICALS L Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹180 cr |
|---|
| Revenue YoY | +35.9% |
|---|
| Operating profit | ₹43.82 cr |
|---|
| Operating margin | 24.3% |
|---|
| Net profit | ₹30.72 cr |
|---|
| Net profit YoY | +55.7% |
|---|
| Net profit QoQ | -2.8% |
|---|
| Net margin | 17.0% |
|---|
| Basic EPS | ₹6.61 |
|---|
| TTM revenue | ₹674 cr |
|---|
| TTM net profit | ₹126 cr |
|---|
| TTM net margin | 18.8% |
|---|
SENORES Q1 FY27 results: what the numbers say
SENORES PHARMACEUTICALS L (SENORES) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹180 cr and a net profit of ₹30.72 cr, translating into earnings per share of ₹6.61.
Compared with the same quarter a year earlier, revenue grew strongly by +35.9% and net profit grew sharply by +55.7%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹43.82 cr, an operating margin of 24.3% versus 17.2% a year ago — a gain of 7.2 percentage points.
SENORES quarter-wise results table
Net profit
₹30.72 cr
+55.7% YoY
Operating profit
₹43.82 cr
+92.6% YoY
SENORES PHARMACEUTICALS L (SENORES) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹180 cr | ₹43.82 cr | ₹30.72 cr | 24.3% | 17.0% | ₹6.61 | +55.7% | -2.8% |
| Q4 FY262026-03-31 | ₹175 cr | ₹38.19 cr | ₹31.61 cr | 21.8% | 18.0% | ₹7.96 | — | -0.2% |
| Q3 FY262025-12-31 | ₹165 cr | ₹46.13 cr | ₹31.66 cr | 28.0% | 19.2% | ₹7.29 | — | -2.2% |
| Q2 FY262025-09-30 | ₹153 cr | ₹41.41 cr | ₹32.38 cr | 27.0% | 21.1% | ₹6.54 | — | +64.1% |
| Q1 FY262025-06-30 | ₹133 cr | ₹22.75 cr | ₹19.73 cr | 17.2% | 14.9% | ₹4.60 | — | — |
| TTM (last 4 quarters) | ₹674 cr | ₹170 cr | ₹126 cr | 25.2% | 18.8% | ₹28.40 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
SENORES quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
SENORES PHARMACEUTICALS L quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹180 cr | ₹175 cr | ₹165 cr | ₹153 cr | ₹133 cr |
|---|
| Total expenses | ₹136 cr | ₹137 cr | ₹119 cr | ₹112 cr | ₹110 cr |
|---|
| Gross profit | ₹114 cr | ₹109 cr | ₹97.83 cr | ₹96.28 cr | ₹71.2 cr |
|---|
| Operating profit (EBIT) | ₹43.82 cr | ₹38.19 cr | ₹46.13 cr | ₹41.41 cr | ₹22.75 cr |
|---|
| Operating margin | 24.3% | 21.8% | 28.0% | 27.0% | 17.2% |
|---|
| Interest cost | ₹7.17 cr | ₹8.46 cr | ₹5.33 cr | ₹6.19 cr | ₹5.04 cr |
|---|
| Profit before tax | ₹39.46 cr | ₹47.4 cr | ₹44.6 cr | ₹40.64 cr | ₹26.49 cr |
|---|
| Tax expense | ₹9.01 cr | ₹10.73 cr | ₹11.02 cr | ₹10.51 cr | ₹5.31 cr |
|---|
| Effective tax rate | 22.8% | 22.6% | 24.7% | 25.9% | 20.0% |
|---|
| Net profit (PAT) | ₹30.72 cr | ₹31.61 cr | ₹31.66 cr | ₹32.38 cr | ₹19.73 cr |
|---|
| Net profit margin | 17.0% | 18.0% | 19.2% | 21.1% | 14.9% |
|---|
| Basic EPS | ₹6.61 | ₹7.96 | ₹7.29 | ₹6.54 | ₹4.60 |
|---|
| Diluted EPS | ₹6.60 | ₹7.96 | ₹7.29 | ₹6.54 | ₹4.60 |
|---|
SENORES results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +35.9% | — | — | — | — |
|---|
| Revenue QoQ | +2.9% | +6.3% | +7.5% | +15.7% | — |
|---|
| Operating profit YoY | +92.6% | — | — | — | — |
|---|
| Operating profit QoQ | +14.7% | -17.2% | +11.4% | +82.0% | — |
|---|
| Net profit YoY | +55.7% | — | — | — | — |
|---|
| Net profit QoQ | -2.8% | -0.2% | -2.2% | +64.1% | — |
|---|
| EPS YoY | +43.7% | — | — | — | — |
|---|
| EPS QoQ | -17.0% | +9.2% | +11.5% | +42.2% | — |
|---|
SENORES annual results history
Full-year performance for SENORES PHARMACEUTICALS L, useful for reading each quarter in context.
SENORES PHARMACEUTICALS L annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹614 cr | ₹381 cr | ₹211 cr | ₹35.33 cr |
|---|
| Total expenses | ₹473 cr | ₹308 cr | ₹179 cr | ₹24.43 cr |
|---|
| Gross profit | ₹357 cr | ₹191 cr | ₹99.61 cr | ₹22.56 cr |
|---|
| Operating profit (EBIT) | ₹141 cr | ₹72.95 cr | ₹31.74 cr | ₹10.89 cr |
|---|
| Operating margin | 23.0% | 19.2% | 15.1% | 30.8% |
|---|
| Interest cost | ₹23.85 cr | ₹20.37 cr | ₹8.5 cr | ₹1.84 cr |
|---|
| Profit before tax | ₹159 cr | ₹70.57 cr | ₹24.94 cr | ₹12.44 cr |
|---|
| Tax expense | ₹37.57 cr | ₹12.23 cr | -₹7.76 cr | ₹4 cr |
|---|
| Effective tax rate | 23.6% | 17.3% | -31.1% | 32.2% |
|---|
| Net profit (PAT) | ₹115 cr | ₹58.56 cr | ₹31.45 cr | ₹8.43 cr |
|---|
| Net profit margin | 18.8% | 15.4% | 14.9% | 23.9% |
|---|
| Basic EPS | ₹26.39 | ₹16.12 | ₹6.83 | ₹1.83 |
|---|
| Diluted EPS | ₹26.39 | ₹16.12 | ₹6.83 | ₹1.83 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹180 cr against ₹133 cr in Q1 FY26, and ₹175 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +2.9%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹136 cr, or 75.7% of revenue, with operating profit grew +92.6% year on year.
Margins, tax and profitability
Net profit of ₹30.72 cr works out to a net margin of 17.0% compared with 14.9% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, SENORES PHARMACEUTICALS L reported profit before tax of ₹39.46 cr, a tax charge of ₹9.01 cr (effective rate 22.8%), interest cost of ₹7.17 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹31.61 cr in Q4 FY26 to ₹30.72 cr in Q1 FY27, a change of -2.8%.
Trailing twelve months and annual context
Across the trailing four quarters SENORES PHARMACEUTICALS L has generated revenue of ₹674 cr and net profit of ₹126 cr, a trailing net margin of 18.8%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹614 cr with net profit of ₹115 cr and EPS of ₹26.39, versus the prior year where revenue grew +61.4% and profit grew +97.0%.
What to watch in the next SENORES quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
SENORES PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
SENORES results coverage
No results report published for SENORES yet — our desk covers each quarter within minutes of the filing.
SENORES quarterly results FAQs
What were SENORES PHARMACEUTICALS L (SENORES) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), SENORES PHARMACEUTICALS L reported revenue of ₹180 cr and net profit of ₹30.72 cr, a change of +55.7% year on year on +35.9% revenue growth. EPS stood at ₹6.61.
What is SENORES profit margin in Q1 FY27?
SENORES PHARMACEUTICALS L posted a net profit margin of 17.0% and an operating margin of 24.3% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹674 cr and net profit ₹126 cr.
Did SENORES results beat the previous quarter?
SENORES PHARMACEUTICALS L net profit changed -2.8% quarter on quarter, from ₹31.61 cr in Q4 FY26 to ₹30.72 cr in Q1 FY27.
When are SENORES PHARMACEUTICALS L (SENORES) quarterly results?
SENORES PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see SENORES latest quarterly results?
Results coverage for SENORES will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the SENORES stock page.
What is SENORES PHARMACEUTICALS L annual revenue and profit?
For FY26, SENORES PHARMACEUTICALS L reported full-year revenue of ₹614 cr and net profit of ₹115 cr, with EPS of ₹26.39.
How many quarterly results has SENORES declared recently?
Past results dates for SENORES will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
